Aarkstore - Interleukin-17 (IL-17) Inhibitors -Pipeline Insights, 2014 - PowerPoint PPT Presentation

View by Category
About This Presentation
Title:

Aarkstore - Interleukin-17 (IL-17) Inhibitors -Pipeline Insights, 2014

Description:

DelveInsights,Interleukin-17 (IL-17) Inhibitors-Pipeline Insights, 2014, report provides comprehensive insights about pipeline drugs across this mechanism of action (MOA). A key objective of the report is to establish the understanding for all the pipeline drugs that fall under Interleukin-17 (IL-17) Inhibitors – PowerPoint PPT presentation

Number of Views:26

less

Write a Comment
User Comments (0)
Transcript and Presenter's Notes

Title: Aarkstore - Interleukin-17 (IL-17) Inhibitors -Pipeline Insights, 2014


1
Interleukin-17 (IL-17) Inhibitors -Pipeline
Insights, 2014
Category Pharmaceuticals Healthcare
  • Browse Complete Report -
  • http//www.aarkstore.com/pharmaceuticals-healthcar
    e/75777/interleukin-17-il-17-inhibitors-pipeline-i
    nsights-2014

2
Summary
  • DelveInsights,Interleukin-17 (IL-17)
    Inhibitors-Pipeline Insights, 2014, report
    provides comprehensive insights about pipeline
    drugs across this mechanism of action (MOA). A
    key objective of the report is to establish the
    understanding for all the pipeline drugs that
    fall under Interleukin-17 (IL-17) Inhibitors.
    This report provides information on the
    therapeutic development based on the
    Interleukin-17 (IL-17) Inhibitors dealing with
    mechanism of action, comparative analysis at
    various stages covering Filed, Phase III, Phase
    II, Phase I, IND filed, Preclinical, Discovery
    and unknown stages, therapeutics assessment by
    monotherapy and combination products and molecule
    type drug information. The report also covers the
    companies information involved in the therapeutic
    development of the products. It also has
    highlighted the discontinued and dormant products.

3
Summary
  • Data Sources
  • The report is built using data and information
    sourced from proprietary databases, primary and
    secondary research and in-house analysis by
    DelveInsight team of industry experts.Secondary
    sources information and data has been collected
    from various printable and non-printable sources
    like search engines, News websites, Government
    Websites, Trade Journals, White papers,
    Magazines, Trade associations, Books, Industry
    Portals, Industry Associations and access to
    available databases.Please note this report
    requires certain updates. We have all the
    information available but require 3 business days
    to complete the process and ensure it is as
    up-to-date as possible. Certain sections in the
    report may be removed or altered based on the
    availability and relevance of data for the
    indicated mechanism of action. 

4
Summary
  • Scope 
  • The report provides a snapshot of the global
    therapeutic landscape of Interleukin-17 (IL-17)
    InhibitorsThe report provides pipeline products
    under drug profile section which includes product
    description, MOA, licensors collaborators,
    development partner and chemical
    informationCoverage of the Interleukin-17
    (IL-17) Inhibitors pipeline on the basis of
    target, MOA, route of administration, technology
    involved and molecule typeThe report reviews key
    players involved in the therapeutics development
    for Interleukin-17 (IL-17) Inhibitors and also
    provide company profilingThe report also gives
    the information of dormant and discontinued
    pipeline projects Pipeline products coverage
    based on various stages of development ranging
    from preregistration till discovery and
    undisclosed stages Provides pipeline assessment
    by monotherapy and combination therapy products,
    stage of development and molecule type

5
Summary
  • Reasons to buyComplete MOA intelligence and
    complete understanding over therapeutics
    development for Interleukin-17 (IL-17)
    InhibitorsIdentify the relationship between the
    drugs and use it for target finding, drug
    repurposing, and precision medicine.Devise
    corrective measures for pipeline projects by
    understanding Interleukin-17 (IL-17) Inhibitors
    pipeline depth and focus of Indication
    therapeutics Developing strategic initiatives to
    support your drug development activities.Optimize
    your portfolio and keep you in touch with the
    rapidly changing pharmaceutical markets, and make
    the best decisions for your business.

6
Summary
  • Develop and design in licensing and out licensing
    strategies by identifying prospective partners
    with the most attractive projects to enhance and
    expand business potential and ScopeProvides
    strategically significant competitor information,
    analysis, and insights to formulate effective RD
    development strategies Modify the therapeutic
    portfolio by identifying discontinued projects
    and understanding the factors that drove them
    from pipelineGaining a Full Picture of the
    Competitive Landscape for Evidence based Decisions

7
Table of Content
  • Interleukin-17 (IL-17) Inhibitors
    OverviewInterleukin-17 (IL-17) Inhibitors
    Disease AssociatedInterleukin-17 (IL-17)
    Inhibitors Pipeline TherapeuticsInterleukin-17
    (IL-17) Inhibitors Therapeutics under Development
    by Companies Interleukin-17 (IL-17) Inhibitors
    Late Stage Products (Filed and Phase
    III)Comparative Analysis Interleukin-17 (IL-17)
    Inhibitors Mid Clinical Stage Products (Phase
    II)Comparative Analysis Interleukin-17 (IL-17)
    Inhibitors Early Clinical Stage Products (Phase I
    and IND Filed)Comparative Analysis Interleukin-1
    7 (IL-17) Inhibitors Discovery and Pre-Clinical
    Stage Products Comparative Analysis Drug
    Candidate ProfilesInterleukin-17 (IL-17)
    Inhibitors Therapeutics Assessment 

8
Table of Content
  • Assessment by Monotherapy ProductsAssessment by
    Combination Products Assessment by Route of
    Administration Assessment by Molecule
    Type Interleukin-17 (IL-17) Inhibitors
    Discontinued Products Interleukin-17 (IL-17)
    Inhibitors Dormant ProductsCompanies Involved in
    Therapeutics Development for Interleukin-17
    (IL-17) Inhibitors Appendix Methodology Contact
    Us Disclaimer

9
List of Tables
  • Number of Products under Development for
    Interleukin-17 (IL-17) Inhibitors by Therapy
    Area, 2014Number of Products under Development
    for Interleukin-17 (IL-17) Inhibitors,
    2014Number of Products under Development by
    Companies Comparative Analysis by Late Clinical
    Stage Products (Filed and Phase III),
    2014Comparative Analysis Mid Clinical Stage
    Products (Phase II), 2014Comparative Analysis
    Early Clinical Stage Products (Phase I and IND
    Filed), 2014Comparative Analysis Discovery and
    Pre-Clinical Stage Products, 2014Drug Candidates
    Profiles

10
List of Tables
  • Interleukin-17 (IL-17) Inhibitors Assessment by
    Monotherapy Products Interleukin-17 (IL-17)
    Inhibitors Assessment by Combination
    Products Interleukin-17 (IL-17) Inhibitors
    Assessment by Route of Administration Interleukin
    -17 (IL-17) Inhibitors Assessment by Stage and
    Route of Administration Interleukin-17 (IL-17)
    Inhibitors Assessment by Molecule
    Type Interleukin-17 (IL-17) Inhibitors
    Assessment by Stage and Molecule
    Type Interleukin-17 (IL-17) Inhibitors
    Therapeutics Discontinued Products Interleukin-17
    (IL-17) Inhibitors Therapeutics Dormant
    ProductsProducts under Development by Companies,
    2014

11
List of Figures
  • Number of Products under Development for
    Interleukin-17 (IL-17) Inhibitors by Therapy
    Area, 2014Number of Products under Development
    for Interleukin-17 (IL-17) Inhibitors, 2014Late
    Clinical Stage Products (Filed and Phase III),
    2014Mid Clinical Stage Products (Phase II),
    2014Early Clinical Stage Products (Phase I and
    IND Filed), 2014Discovery and Pre-Clinical Stage
    Products, 2014Interleukin-17 (IL-17) Inhibitors
    Assessment by Monotherapy Products Interleukin-17
    (IL-17) Inhibitors Assessment by Combination
    Products Interleukin-17 (IL-17) Inhibitors
    Assessment by Route of Administration Interleukin
    -17 (IL-17) Inhibitors Assessment by Stage and
    Route of Administration Interleukin-17 (IL-17)
    Inhibitors Assessment by Molecule
    Type Interleukin-17 (IL-17) Inhibitors
    Assessment by Stage and Molecule Type

12
Related Reports
  • OncoPlex Diagnostics - Pharmaceuticals
    Healthcare - Deals and Alliances Profile
  • MetaStat, Inc. - Pharmaceuticals Healthcare -
    Deals and Alliances Profile
  • Advanced Cell Diagnostics, Inc. - Pharmaceuticals
    Healthcare - Deals and Alliances Profile
  • Recordati S.p.A. (REC) - Pharmaceuticals
    Healthcare - Deals and Alliances Profile
  • Global Gene Expression Market 2015-2019
  • Ascension Health - Pharmaceuticals Healthcare -
    Deals and Alliances Profile
  • Accretive Health, Inc. (ACHI) - Strategic SWOT
    Analysis Review
  • Jazz Pharmaceuticals plc (JAZZ) - Financial and
    Strategic SWOT Analysis Review
  • Pharmstandard (PHST) - Financial and Strategic
    SWOT Analysis Review
  • GLG Life Tech Corporation (GLG) - Financial and
    Strategic SWOT Analysis Review

13
  • Interleukin-17 (IL-17) Inhibitors -Pipeline
    Insights, 2014
  • Published Dec. 2014 60 Pages
  • DelveInsights,Interleukin-17 (IL-17)
    Inhibitors-Pipeline Insights, 2014, report
    provides comprehensive insights about pipeline
    drugs across this mechanism of action (MOA).

    Price

Format Price
PDF 1250
Site Licence 2500
Enterprise Wide Licence 4000
14
Contact Us
Office Office No. - 809, 8th Floor,B-Wing,
Mahaavir Icon, Plot No.- 89 90,
Sector-15,CBD-Belapur, Navi Mumbai
400614, Maharashtra, India. Telefax No 91 22
4127 6660 24/7 Online Support 91
9987295242 General Inquiries 91 - 22 2756 4953
  • You Can Visit http//www.aarkstore.com
  • OR Mail us at contact_at_aarkstore.com
  • Blog
  • http//www.aarkstore.com/blog/
  • Conference
  • http//conference.aarkstore.com/
  • News
  • http//www.aarkstore.com/news
About PowerShow.com